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Laboratory Values for Vector-Borne Illness — Experience
in an Urban Gastroenterology Practice
Michael D. Erdman, MBBS,1 Niloofar Kossari, MS,1 Jessica Ye, BS,1 Kristen H. Reynolds, MD,2
Emily Blodget, MD,3 B. Robert Mozayeni, MD,4 Farshid Sam Rahbar, MD1
Los Angeles Integrative Gastroenterology & Nutrition, Los Angeles, CA; 2Aurora Wiselives Center, Advocate Aurora
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Purpose	
In the clinical setting, it is not common practice to consider a vector bite, such as from a tick or flea, to
be a contributing factor to chronic digestive symptoms. This article investigates associations we have
observed among symptomatic patients and positive blood tests for vector-borne illness (VBI).
Methods	
Patients who visited an urban gastroenterology clinic over a 3-year period were retrospectively
reviewed. A total of 270 patients presenting with a constellation of digestive symptoms — and who
had no apparent digestive pathology and reported no prior diagnosis or treatments for VBI — were
analyzed. Before the initial visit, all patients completed a review of systems medical history form,
which comprised 19 gastrointestinal (GI) symptoms and 73 non-GI-related symptoms and conditions.
Patients were tested for small intestinal bacterial overgrowth (SIBO) by lactulose breath test. VBI
(babesiosis, ehrlichiosis, anaplasmosis, bartonellosis, borreliosis) was established using 1 or more
of several blood tests. Odds ratio (OR) analysis determined associations between exposure to VBI,
SIBO, and presenting symptoms/conditions. Two age groups (≤35 years and ≥36 years) were studied
using Cochran-Mantel-Haenszel stratum-based test.
Results 	A higher OR (2.03, 95% CI: 1.5–3.6) was found between patients with ≥3 digestive symptoms and
positive blood tests for ≥1 VBI. Five of the 19 GI symptoms were independently associated with VBIpositive samples: food intolerance, indigestion, nausea/vomiting, constipation, and heartburn. A similar
association in patients with ≥3 non-GI symptoms (OR: 2.83, 95% CI: 1.3–6.4) was observed. Five of
the 73 non-GI symptoms/conditions were independently associated with VBI-positive samples: chest
pain, shortness of breath, extremity or joint pain, anxiety, and night sweats. Having ≥3 of any digestive
or nondigestive symptoms generated significant relative risk of being VBI-positive. Presence of SIBO
alone did not identify significant relative risk for a VBI, and age was not a confounder.
Conclusions	Findings revealed an association between positive blood tests for vector-borne illness and chronically
symptomatic patients regardless of whether symptoms were digestive or nondigestive. The
manifestation of 3 or more gastrointestinal and/or extraintestinal symptoms should raise suspicion for
a VBI. (J Patient Cent Res Rev. 2021;8:39-47.)
Keywords	
bloating; functional bowel disorders; malabsorption; small intestinal bacterial overgrowth; SIBO;
gastrointestinal symptoms; digestive symptoms; vector-borne illness; tick-borne; Lyme disease

T

he human intestinal tract is composed of a
complex and interactive community of 100
trillion microbial cells.1 An imbalance of the gut
microbiome may have serious health consequences,2

Corresponding author: Farshid Sam Rahbar, MD, FACP,
Los Angeles Integrative Gastroenterology & Nutrition,
Los Angeles, CA 90067 (drrahbar.ilads@laintegrativegi.com)

Original Research

including small intestinal bacterial overgrowth (SIBO).
SIBO is excessive bacteria in the upper gastrointestinal
(GI) tract. One may quantitatively define SIBO as an
increase in the number of bacteria in the small bowel
exceeding 105 organisms/mL.3,4 Some authorities may
consider bacterial count as high as 103 as a threshold
for having SIBO.5 Common symptoms related to SIBO
are abdominal bloating, distension or pain, flatulence,
nausea, dyspepsia, diarrhea, constipation, fatigue, and
malabsorption symptoms.4,6
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According to the World Health Organization, vectorborne illnesses (VBI) account for more than 17% of all
infectious diseases.7 In the United States, the number
of reported cases of disease from mosquito, flea, and
tick bites has tripled from 2004 to 2016, totaling
more than 640,000 reported cases over that period.8
Recollection of a tick or vector bite is not needed to
consider the diagnosis of VBI because the embedded
vector/tick secretes a compound that anesthetizes the
skin at the point of entry.9 Thus, most people will not
feel or remember a bite.9 Ticks can infect humans with a
variety of bacteria, viruses, fungi, and protozoans, all at
the same time in a single bite.10
Borrelia burgdorferi sensu stricto, as well as species of
the B. burgdorferi sensu lato complex, cause borreliosis,
otherwise known as Lyme disease. Diagnosis of the acute
Borrelia infection is generally made based on a subject’s
possible exposure to infected ticks, typical symptoms,
and physical findings (eg, characteristic erythema
migrans rash). Statistics reported by the U.S. Centers
for Disease Control and Prevention (CDC) suggest that
each year more than 300,000 individuals in the United
States become infected with borreliosis, though the vast
majority of these infections go unreported.8 A published
survey of 3090 patients with chronic Lyme disease found
that more than 50% had coinfections, with 30% reporting
2 or more coinfections. The most common coinfections
were babesiosis (32%) and bartonellosis (28%).11 These
coinfections with borreliosis can exacerbate symptoms or
induce similar clinical manifestations.12
Babesiosis is caused by microscopic parasites, with
Babesia microti being the most common species found in
Americans and B. duncani noted mainly on the U.S. west
coast.7 Babesia parasites infect and lyse red blood cells
and therefore may cause hemolytic anemia in addition
to nonspecific flu-like symptoms such as fever, chills,
body aches, nausea, or fatigue.13 The U.S. Food and
Drug Administration (FDA) has determined babesiosis
to be a relevant transfusion-transmitted infection. As per
FDA guidelines in July 2018, it is now recommended to
screen donor blood for human babesiosis.14 This policy
implies that there are many “healthy” donors who feel
well enough to donate blood, yet they may be turned down
because of the detection of Babesia in their bloodstream.
According to the FDA, the vast majority of B. microti
infections are asymptomatic and never diagnosed.14 In
addition, the duration of B. microti infection in healthy
adults is not clearly known, and the parasitemia may
persist for more than 2 years.14 Currently, the U.S.
blood screening policy does not recommend testing for
B. duncani, despite its relatively wide distribution.9,15
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Bartonellosis is caused by gram-negative Bartonella
spp. bacteria. Common diseases caused by Bartonella
are cat-scratch disease (B. henselae), Carrion’s disease
(B. bacilliformis), and trench fever (B. quintana).16
Symptoms range from lymphadenopathy to systemic
disease, with the severity and presentation of illness
related to an individual’s immune status.17
The study of VBI presented herein focuses on this most
prevalent trio — borreliosis,18 Bartonella spp., and
Babesia spp. — along with testing for Ehrlichia and
Anaplasma. We undertook this research based on the
patient population that presented to our gastroenterology
clinic, for whom we could not explain their persistent or
recurrent digestive symptoms or difficult-to-treat SIBO.
We speculated that patients with underlying VBI might
present primarily with chronic digestive manifestations,
leading to unfavorable SIBO treatment outcomes.
The primary goal of this retrospective study was to
investigate the degree of association between positive
hematological markers for VBI and the constellation of
digestive and nondigestive symptoms and conditions
in a patient population referred for potential SIBO,
specifically, to better understand which subset of
symptoms/conditions would indicate the possibility of
an underlying VBI. We also evaluated the association
between diagnosis of SIBO and positive hematological
markers for VBI.

METHODS

A retrospective study of patients seen at an urban GI
practice based in Los Angeles, California, from November
4, 2015, to October 12, 2018, was conducted under
institutional review board exemption protocol (Pearl IRB
no. 19-LAGA-101). First-time attendees to the practice,
either self-referred or referred by another physician,
were eligible for the study. Patients presented with a
constellation of digestive symptoms, had no obvious GI
pathology, and to the best of the practice’s knowledge,
had no prior diagnosis or treatments for VBI. These
patients had clinical presentations and multisystemic
manifestations that suggested the possibility of an
underlying systemic illness.
At the initial visit, all patients completed a review of
systems medical history form, which comprised 19
GI symptoms and 73 non-GI-related symptoms and
conditions. The practice requested that patients circle
any symptom or condition that they were experiencing.
Symptomatic patients — symptoms being ones that
patients circled on their own — who completed a SIBO
breath test and blood sampling for VBIs after consultation
with the physician were included in the study. Any
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candidate who did not complete a breath test or blood
testing for VBI was excluded from the study.
Methods to Determine Positive Results

Small Intestinal Bacterial Overgrowth Test. For SIBO
analysis, we collected samples using the QuinTron breath
test kit (QuinTron Instrument Company) and analyzed
according to the protocols outlined by the 2016 SIBO
consensus criteria.19 Any of the following 3 results
was considered sufficient evidence of SIBO positivity:
methane of ≥10 ppm in the first 80 minutes; hydrogen rate
of rise of ≥20 ppm in the first 80 minutes; and hydrogen
baseline of ≥20 ppm. These criteria are more stringent
than the currently defined consensus for SIBO-positive
results,19 placing the cutoff for the final time spot for
gas measurement at 80 minutes as opposed to 90 or 120
minutes. This was done to avoid borderline cases.
Vector-Borne Illness Testing. For positive VBI,
testing included Lyme immunoblot,20 general western
blot,20 polymerase chain reaction (PCR),21 indirect
immunofluorescent antibody,22 and fluorescent in situ
hybridization (FISH) analysis.20 Detailed information
about the reference clinical laboratory protocols is
provided in Online Appendix A.
There are different schools of thought when it comes
to clinical lab testing models for borreliosis. To reduce
controversy and ambiguity, only those patients who met
CDC criteria for B. burgdorferi western blot interpretation
were incorporated, meaning that we excluded bands 31kD
and 34kD for western blot interpretation, thereby increasing
specificity. The enzyme immunoassay screening test also
was excluded as a prerequisite for considering western blot
results positive, out of the desire for higher sensitivity to
ensure a potential association was not missed in this study,
which was primarily intended to formulate a hypothesis
that we hope will inform subsequent studies.
The biological rationale for these decisions was as
follows: Patients with VBI are often deficient in their
IgA and IgG total antibody levels. In other words, had we
relied on the screening test as a prerequisite to western
blot testing, we might have missed a substantial portion
of this cohort and therefore any association. Additionally,
in the last one-third of our study, patients were tested for
borreliosis by immunoblot and did not have a western
blot test. Immunoblot testing does not follow the same
enzyme immunoassay first-step prerequisite.
Lyme Immunoblot. B. burgdorferi sensu lato-specific
IgM and IgG antibodies were detected in human serum
samples by the Lyme immunoblot test.20 Recombinant
proteins to the following Borellia species — B. burgdorferi
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B31, B. burgdorferi 297, B. californiensis, B. mayonii,
B. spielmanii, B. afzelii, B. garinii, and B. valaisiana —
were sprayed at specific positions onto a nitrocellulose
membrane and cut into strips. These strips were then used
to detect B. burgdorferi sensu lato-specific antibodies in
patient serum, as described by Liu et al.20 The blots were
interpreted according to CDC/New York State criteria.
IgM immunoblot was deemed positive if 2 of the following
3 bands were present: 23, 39, and 41kDa. IgG immunoblot
was deemed positive if 5 of the following 10 bands were
present: 18, 23, 28, 30, 39, 41, 45, 58, 66, and 93kDa.
Tick-Borne Relapsing Fever (TBRF) Immunoblot. This
test is a qualitative immunoblot assay that detects IgM and
IgG antibodies in human serum to the following TBRFassociated Borrelia species: B. miyamotoi, B. hermsii,
B. turicatae, and B. coriaceae. Recombinant TBRF
Borrelia antigens were sprayed at specific positions onto
a nitrocellulose membrane and cut into strips. These strips
were used to detect TBRF Borrelia-specific antibodies in
patient serum as described for Lyme immunoblots.23 TBRF
immunoblot for IgM or IgG was considered positive if at
least 1 antigen from at least 2 of 4 groups — 70-75kDa,
GlpQ, 21-23kDA, and 41kDA — was detected.
Lyme Multiplex PCR Followed by Confirmation by DotBlot Assay. Lyme multiplex PCR is a 3-step amplified
nucleic acid assay that detects specific DNA sequences
of OspA plasmid and P66 of B. burgdorferi sensu
stricto, B. afzeli, B. andersonii, and B. garinii in clinical
specimens.21 Gene fragments were hybrid-selected with 3
biotin-labeled capture probes (Online Appendix A). Probe
A and Probe B were designed to selectively bind OspA
and Probe C to P66 gene sequences, respectively, that are
conserved in different B. burgdorferi strains. The hybridselected B. burgdorferi-specific DNA fragments were
captured on to streptavidin beads and washed to remove
debris and excess probes. The purified bound DNA was
eluted and amplified using 2 sets of primers, an OspA set
described by Mouristen et al24 and a P66 gene-specific
set described by Rosa et al25 (Online Appendix A). The
amplified PCR products were detected in a final dot-blot
assay by two B. burgdorferi-specific 5′ digoxigeninlabeled probes using the Roche hybridization kit (Roche
Molecular Diagnostics). The first probe targeted the
genomic flagellin gene, and the second probe targeted
the plasmid-encoded OspA gene (Online Appendix A).
A sample is considered positive if the dot-blot is positive.
Indirect Immunofluorescent Antibody. Respective
indirect immunofluorescent antibody tests detect IgM and
IgG antibodies to Babesia species B. microti, B. duncani,
and B. henselae in human serum. The human monocytic
ehrlichiosis immunofluorescent antibody test detects IgM
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and IgG antibodies to Ehrlichia chaffeensis, the causative
agent of ehrlichiosis in human serum. The human
granulocytic anaplasmosis immunofluorescent antibody
test is used to detect IgM and IgG antibodies to Anaplasma
phagocytophilum, the causative agent of anaplasmosis in
human serum. A patient sample is considered positive if
the titer is ≥20 for IgM and ≥40 for IgG.
Fluorescent In Situ Hybridization. The ribosomal
RNA of Babesia (ring or merozoite form) was directly
detected in a blood smear by FISH assay using Babesiaspecific DNA probes labeled with fluorescent dyes.26
The sample was considered positive if fluorescing rings
or merozoites are present inside at least 2 red blood
cells (RBCs). This test has excellent sensitivity and
specificity over standard Giemsa-stained smears for
the presence of intraerythrocytic parasites (piroplasts)
in red blood cells.26 The Bartonella FISH test, which
is similar to FISH for Babesia, also was performed on
ethylenediaminetetraacetic-acid whole blood smears.
The sample was considered positive if fluorescing rodshaped bodies were detected in the smear.23 The FISH
test detects bacteria of the genus Bartonella, including
B. vinsonii, B. berkhoffii, B. henselae, and B. quintana,
and provides a significant increase in specificity over
the standard gram stain for the presence of Bartonella in
whole blood smears.23
Statistical Analysis

Associations between symptoms and test results
were quantified using odds ratios (OR) and their 95%
confidence intervals (CI). We analyzed the confounding
effect of age using the Cochran-Mantel-Haenszel method.

RESULTS

A total of 270 patients seen from November 4, 2015, to
October 12, 2018, met the criteria for our retrospective
study. Selected patients presented with a variety of
digestive (ie, GI) symptoms and nondigestive (ie, nonGI) symptoms/conditions and were found to have SIBO
(n=173) or not have SIBO (n=97) and have VBI (n=136)
or not have VBI (n=134). Patient demographics are
outlined in Table 1.
Association Between SIBO and VBI

Figure 1 shows that out of 270 patients, 173 patients
had SIBO. When comparing the SIBO-positive and
SIBO-negative groups, both showed approximately 50%
prevalence for VBI. The calculated OR of 0.99 (95%
CI: 0.6027–1.6294) negated a clear cause-and-effect
association between VBI and SIBO, meaning that patients
with evidence of at least 1 positive blood test for a VBI
were no more likely to have SIBO than patients who had
negative VBI blood tests.
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Composition of GI Symptoms and Association
With VBI

We studied 19 GI symptoms that patients circled on
their first-visit intake form. As shown in Table 2, 5 of
the 19 GI symptoms had significantly higher odds when
determining an association with VBI-positive blood
samples (OR range: 1.65–2.01). These 5 symptoms
were food intolerance, indigestion, nausea/vomiting,
constipation, and heartburn.
Table 3 highlights the importance of the number of GI
symptoms when determining an association with positive
blood tests for VBI. Having 3 or more of any of the 19 GI
symptoms was associated with positive VBI.

Table 1. Demographic Features of Patients (N=270)
Demographic

n

Female, n

170

Male, n

100

Age in years, median (range)

39 (13–76)

SIBO-positive, n

173

SIBO-negative, n

97

VBI-positive, n

136

VBI-negative, n

134

Age of ≤35 years, n

110

Age of ≥36 years, n

160

Age of ≤35 years with VBI, n

59

Age of ≥36 years with VBI, n

77

SIBO, small
intestinal bacterial overgrowth; VBI, vectorFIGURE
LEGENDS
borne illness.

SIBO (+)
173 patients
270 patients
with symptoms
SIBO (-)
97 patients

VBI (+)
87 patients
VBI (-)
86 patients

Compare

VBI (+)
49 patients
VBI (-)
48 patients

Figure 1. Prevalence of blood test-verified vector-

Figure
1. Prevalence
of bloodin
test-verified
vector-borne
illness
(VBI) in patients
borne
illness (VBI)
patients
with and
without
smallwith small intestinal
bacterial overgrowth (SIBO) in a 270-patient retrospective study conducted from November 4, 2015, to
intestinal
bacterial
overgrowth
(SIBO).
Analysis
October 12, 2018. SIBO (+) stands for SIBO-positive; SIBO (-), SIBO-negative; VBI (+), VBI-positive; an
VBI
(-), VBI-negative.
comparing
all VBI subgroups yielded an odds ratio of

0.99 (95% CI: 0.6027–1.6294). SIBO (+) stands for
SIBO-positive; SIBO (-), SIBO-negative; VBI (+), VBIpositive; and VBI (-), VBI-negative.

Original Research

Table 2. Associations Between 19 Individual Digestive Symptoms and Positive Blood Tests for Vector-Borne
Illness in a Retrospectively Reviewed 270-Patient Sample
VBI (n=136)

Non-VBI (n=134)

Gastrointestinal symptom

Case

Control

Case

Control

Odds ratio

95% CI

Abdomen pain
Acidic stomach
Altered bowel
Bloating
Constipation
Dark urine
Diarrhea
Difficulty swallowing
Feeding difficulty
Food intolerance
Heartburn
Indigestion
Irregular bowel movements
Lack of appetite
Nausea vomiting
Need for laxatives
Rectal bleeding
Weight loss
Weight gain

75
42
52
111
62
9
47
15
6
63
37
53
48
30
48
15
12
31
24

61
94
84
25
74
127
89
121
130
73
99
83
88
106
88
121
124
105
112

70
33
39
101
40
3
32
12
2
46
21
36
40
18
31
11
9
23
22

64
101
95
33
94
131
102
122
132
88
113
98
94
116
103
123
125
111
112

1.124
1.3675
1.5079
1.4507
1.9689
3.0945
1.6833
1.2603
3.0462
1.651
2.0111
1.7383
1.28
1.8239
1.8123
1.3862
1.3441
1.4248
1.0909

0.6964–1.8142
0.8005–2.3362
0.9069–2.5073
0.8078–2.6051
1.1933–3.2487
0.8190–11.6918
0.9892–2.8644
0.5665–2.8040
0.6037–15.3703
1.0107–2.6968
1.1041–3.6631
1.0392–2.9077
0.7694–2.1356
0.96–3.4623
1.0627–3.0906
0.6120–3.1395
0.5469–3.3035
0.7806–2.6009
0.5781–2.0587

In this table, “Case” refers to patients who were positive for the symptom. “Control” refers to patients who were negative
for the symptom. “VBI” refers to patients with positive blood tests for vector-borne illness. “Non-VBI” refers to patients with
negative blood tests for vector-borne illness.

Table 3. Associations Between Number of Presenting Gastrointestinal (GI) Symptoms and Blood Test Results
for Vector-Borne Illness in a Retrospectively Reviewed 270-Patient Sample
VBI (n=136)
GI symptoms

Case

Non-VBI (n=134)

Control

Case

Control

Odds ratio

95% CI

0 or more

136

0

134

0

1.0149

0.0200–51.5209

1 or more
2 or more
3 or more
4 or more
5 or more
6 or more
7 or more

125
119
111
100
88
70
53

11
17
25
36
48
66
83

126
113
92
72
60
42
27

8
21
42
62
74
92
107

0.7215
1.3009
2.027
2.392
2.2611
2.3232
2.5306

0.2808–1.8540
0.6529–2.5919
1.1497–3.5735
1.4359–3.9847
1.3859–3.6891
1.4143–3.8162
1.4674–4.3639

In this table, “Case” refers to patients with GI symptoms that met the specific parameter criteria. “Control” refers to patients
with GI symptoms that did not meet specific parameter criteria. “VBI” refers to patients with positive serology for vector-borne
illness. “Non-VBI” refers to patients with negative serology for vector-borne illness.

Composition of Non-GI Symptoms and Association
With VBI

We studied 73 non-GI symptoms/conditions that
patients circled on their first-visit intake form. As
shown in Table 4, 5 symptoms independently had
higher odds when determining an association with
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VBI-positive blood samples (OR range: 1.79–2.32).
These 5 non-GI symptoms included extremity and
joint pain, chest pain, shortness of breath, anxiety, and
night sweats. For a complete table of the 73 non-GI
symptoms/conditions with their respective OR, see
Online Appendix B.
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Table 4. Five Independent Nondigestive Symptoms That Demonstrated an Association With Positive Blood
Tests for Vector-Borne Illness in a Retrospectively Reviewed 270-Patient Sample
VBI (n=136)
Symptom

Non-VBI (n=134)

Case

Control

Case

Control

Odds ratio

95% CI

43
29
37
90
34

93
107
99
46
102

27
14
19
70
19

107
120
115
64
115

1.8323
2.3231
2.2621
1.7888
2.0175

1.0511–3.1941
1.1663–4.6272
1.2230–4.1841
1.0948–2.9229
1.0837–3.7560

Extremity and joint pain
Chest pain
Shortness of breath/Air hunger
Anxiety
Night sweats

In this table, “Case” refers to patients who were positive for the symptom. “Control” refers to patients who were negative
for the symptom. “VBI” refers to patients with positive blood tests for vector-borne illness. “Non-VBI” refers to patients with
negative blood tests for vector-borne illness.

Table 5. Associations Between Number of Presenting Nongastrointestinal (Non-GI) Symptoms and Blood Test
Results for Vector-Borne Illness in a Retrospectively Reviewed 270-Patient Sample
VBI (n=136)
Non-GI symptoms

Non-VBI (n=134)

Case

Control

Case

Control

Odds ratio

95% CI

1 or more

108

28

97

37

1.4713

0.8385–2.5817

2 or more

54

82

40

94

1.5476

0.9341–2.5640

3 or more

23

113

9

125

2.8269

1.2557–6.3645

In this table, “Case” refers to patients with non-GI symptoms that met the specific parameter criteria. “Control” refers to
patients with non-GI symptoms that did not meet specific parameter criteria. “VBI” refers to patients with positive blood tests
for vector-borne illness. "Non-VBI" refers to patients with negative blood tests for vector-borne illness.

Table 5 indicates the importance of the number of non-GI
symptoms when determining an association with positive
blood tests for VBI. It was only when 3 or more of any of
the 73 non-GI symptoms/conditions were present that an
association with VBI testing was detected.
Table 6 depicts detailed breakdown of multiple parameters
shown on the left, and the positive blood test results of the
9 different groups of infections (Lyme, TBRF group, B.
microti, B. dancani, human monocytic ehrlichiosis, human
granulocytic anaplasmosis, B. henselae, Rickettsia rickettsii,
and Rickettsia typhi). Of interest, positive blood markers for
B. duncani were most prevalent in every parameter studied.
The Cochran-Mantel-Haenszel statistical test was used to
study age as a possible confounder. According to the test
data in patients who were ≤35 years old versus those who
were ≥36 years old, age was not a confounding factor (χ2:
10.26, OR: 2.5, 95% CI: 1.45–4.3). Gender also did not
appear to be a confounding factor.

DISCUSSION

In the setting of a face-to-face evaluation of a patient
in the exam room, it is uncommon to consider a vector
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bite, such as one from a tick or flea, to be the primary
contributor to digestive symptoms and chronic illness.
However, our experience suggests the contrary. In our
study population, patients presented with chronic GI
symptoms and evidence of positive laboratory markers
for VBI and yet did not have classic acute presentation.
Tick and/or other vector-borne diseases are generally
recognized based on their acute signs — a scenario not
typically encountered in gastroenterology practices. The
history of medicine, however, reveals that many of the
diseases caused by other unrelated microbial agents may
indeed become persistent without a patient’s recollection
of an acute illness. Examples of these include tuberculosis,
toxoplasmosis, Zika virus, syphilis, and more.27-30
One example of a microbe that may be chronically
present in the human body, with or without symptoms,
is Babesia. In our own study observation, B. duncani
was the most common pathogen identified by blood
test analysis. As noted in the introduction, blood bank
screening currently includes B. microti only, which
implies that those infected with B. duncani might not
be identified.
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1
1
0
0
0
0
0
2
1
1
1
1
2
1
1

21
9
12
8
8
4
4
20
15
13
5
5
30
21
9

All female patients (170)
All male patients (100)
All patients with ≥3 GI symptoms
(203)
Female patients with ≥3 GI
symptoms (136)
Male patients with ≥3 GI
symptoms (67)
Patients ≤35 years old (110)
Female patients ≤35 years old
(71)
Female patients ≤35 years old
with ≥3 GI symptoms (63)
Male patients ≤35 years old (39)
Male patients ≤35 years old with
≥3 GI symptoms (26)
Patients ≥36 years old (160)
Female patients ≥36 years old (99)
Female patients ≥36 years old
with ≥3 GI symptoms (73)
Male patients ≥36 years old (61)
Male patients ≥36 years with ≥3
symptoms (41)
Patients with positive VBI test and
≥3 GI symptoms (109)
Female patients with positive VBI
test and ≥3 GI symptoms (69)
Male patients with positive VBI
test and ≥3 GI symptoms (40)
2

2

4

2
2

3
1
1

0
0

1

1
1

2

2

2
2
4

4

5

5

10

3
3

7
4
4

2
2

1

3
1

5

5

5
5
10

10

8

23

31

5
3

17
12
9

6
5

14

20
14

8

23

26
11
31

37

IFA

FISH

B.
IFA

B.
duncani
IFA

HME

HME

IFA

HGA

HGA

IFA

B.
henselae
FISH

B.

Bartonella

5

12

17

3
1

13
10
6

4
4

6

10
6

5

12

16
7
17

23

5

11

16

2
2

10
8
8

3
3

3

6
3

5

11

11
5
16

16

1

2

3

0
0

3
3
2

1
1

0

1
0

1

2

3
1
3

4

8

19

27

5
4

21
16
12

4
4

7

11
7

8

19

23
9
27

32

12

28

40

7
5

25
18
14

7
7

14

23
16

12

27

34
14
40

48

5

7

12

3
2

6
3
3

4
3

4

9
5

5

7

8
7
12

15

2

9

11

3
2

10
7
6

0
0

3

3
3

2

9

10
3
11

13

2

2

4

1
1

3
2
2

1
1

0

1
0

2

2

2
2
4

4

4

5

9

5
3

9
5
4

1
1

1

2
1

4

5

6
5
9

11

2

1

3

2
2

3
1
1

1
0

0

1
0

2

1

1
3
3

4

4

7

11

4
3

9
5
3

2
1

4

6
4

4

7

9
6
11

15

2

3

5

1
1

3
2
2

1
1

1

2
1

2

3

3
2
5

5

2

5

7

1
1

5
4
3

3
1

2

5
2

2

5

6
4
7

10

IgG IgM IgG FISH IgM IgG IgM IgG IgM IgG IgM IgG FISH
+ve +ve +ve +ve +ve +ve +ve +ve +ve +ve +ve +ve +ve

Immunoblot serum

B.
microti

Babesia

2

1

3

1
1

1
0
0

1
1

1

2
1

2

1

1
2
3

3

IgG
+ve

IFA

1

1

2

1
1

1
0
0

0
0

1

1
1

1

1

1
1
2

2

IgG
+ve

IFA

R.
R.
rickettsii typhi

Rickettsia

FISH, fluorescence in situ hybridization; GI, gastrointestinal; HGA, human granulocytic anaplasmosis; HME, human monocytic ehrlichiosis; IFA, indirect immunofluorescence
assay; IgG, immunoglobulin G; IgM, immunoglobulin M; SP, serum plasmid; TBRF, tick-borne relapsing fever; WBP, whole blood plasmid.

+ve refers to positive results.

1
1
2

23
9
30

All patients (270)

2

32

Variable (n)

Multiplex

TBRF

IgG SP PCR WBP PCR IgM
+ve
+ve
+ve
+ve

IgM
+ve

Immunoblot
western

Lyme

Borrelia

Table 6. Detailed Analysis of All Vector-Borne Illness, Sorted by Type of Infection and Varying Parameters

Another example is the concept of “chronic Lyme
disease,” which has been an area of ongoing controversy
and scientific debate. A case definition for chronic Lyme
disease, with supportive literature, has been proposed
as a multisystem illness with a wide range of symptoms
that are either continuously or intermittently present for
a minimum of 6 months.12 These concepts should point
to the consideration that “stealth” or persistent infections
are a reality and may underlie many human maladies.
Our data suggest that one should consider an underlying
microbial etiology for chronic or unexplained digestive
conditions that do not resolve. It is well described in the
literature that microbial involvement may lead to immune
dysregulation,31 such as Th1, Th2,32 Treg,33 and Th17
imbalances,34 mast cell activation,35 and dysautonomia,36
to name a few. The clinical manifestation often surfaces
as a result of epigenetic factors, exposure to life stressors,
alcohol, environmental toxins, and overall allostatic load.
Positive blood testing for VBI may suggest prior exposure
to a specific organism as opposed to an active infection.
The argument would then be that the clinical picture is
dictated by either an infection or as a consequence of
prior exposure with subsequent immune dysregulation.
Limitations

Patient age (ie, being younger [≤35 years] or older [≥36
years]) was not determined to be a confounding factor.37
Possibly there are other confounders, such as gender,
height, weight, and zip code, that we did not fully analyze
— a limitation of the study. We hope this article will
function as a prompt to further prospective studies that
factor in such potential confounders. This retrospective
study has other limitations. For one, symptoms were not
quantified. In addition, given the nature of our practice,
we may have received a skewed population of patients
and findings may not be generalizable to other practices.
Finally, SIBO appears to be common in patients with
positive markers for VBI; however, we found that SIBO
was equally prevalent in those without VBI. Considering
that we used diagnostic criteria more stringent for
detecting SIBO than currently recommended guidelines,
it is possible that the association was missed.
Future Research

Bearing in mind the limitations of our study, we believe
that there is still value in the information provided, as our
clinical and statistical findings suggest that underlying
VBI may contribute to the etiology of GI symptoms.
Because cause-and-effect cannot be established based
on this study, we believe this hypothesis warrants further
research. We propose that while many patients with
digestive symptoms may strictly have a GI disease,
one should at least consider the possibility of an
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unidentified VBI dysregulating the immune system38,39
and contributing to ongoing illness.

CONCLUSIONS

Pattern recognition is the key principle in making a
proper diagnosis. In evaluating patients with chronic,
nonspecific, recurrent, or unexplained digestive
symptoms, health care providers should incorporate
a detailed review of systems. The manifestation of 3
or more gastrointestinal symptoms and/or 3 or more
extraintestinal symptoms should raise suspicion for a
vector-borne illness. Recognizing underlying VBI may
improve our understanding of persistent infections,
resultant immune dysregulation, and their contribution
to chronic, complex illness. This article can ignite
additional research in this area.
Patient-Friendly Recap
• Disease caused by insect or tick bites, referred to
as vector-borne illness, often goes undiagnosed.
Similarly, many patients with irritiable bowel-type
symptoms actually have SIBO, or small intestinal
bacterial overgrowth.
• The authors studied whether patients seen for
chronic unexplained symptoms were more likely to
have underlying vector-borne illness and whether
such illness was associated with a SIBO diagnosis.
• They found that while many in this patient
population did indeed have SIBO, vector-borne
illness was no more common in those who did
than those who didn’t. Importantly, presence of 3
or more chronic symptoms of any kind should raise
suspicion for vector-borne diseases.
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